A Phase I Safety and Tolerability Study of T-1101 (Tosylate) as a Oral Powder for Constitution (OPC) in Patients With Advanced Refractory Solid Tumors
Unknown Phase 1 NCT03195764
Study Description
T-1101 (Tosylate) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by Taivex Therapeutics Corp. T-1101 (Tosylate) is a potent anti-cancer agent in numerous human cancer cell lines. In addition, oral administration of T-1101 (Tosylate) showed tumor growth inhibition in different mouse xenograft models of human cancers. In this study, safety, tolerability and PK of T-1101 (Tosylate) will be evaluated and also the recommended dose and regimen(s) to initiate Phase 2 will be determined.
Study Details
- Registry ID:
- NCT03195764
- Conditions:
- Advanced Refractory Solid Tumors
- Phase:
- Phase 1
- Target Enrollment:
- 21 participants
- Start Date:
- Age Range:
- 20–999 years
- Healthy Volunteers:
- No
Study Locations (4 sites)
-
China Medical University Hospital
Taichung City 404327, Taiwan -
National Cheng Kung University Hospital
Tainan, Taiwan -
Taipei Medical University Hospital
Taipei, Taiwan -
National Taiwan University Hospital
Taipei, Taiwan
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.